StockData
HUTCHMED (China) Ltd logo

HUTCHMED (China) Ltd (HCM) stock

HCMNasdaqPharmaceutical PreparationsAlso trades as HMDCF
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026Score 5/30
$14.40−0.33 (-2.24%)

Close on Nov 17, 2026Market cap $2.51BP/E 5.5Yield –

Earnings

HUTCHMED (China)'s quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
Reaffirmed
Jul 30, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of HUTCHMED (China)'s earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2026ended Jun 30, 2026Jul 30, 2026before the open–––Release
Q4 FY2025ended Dec 31, 2025Mar 5, 2026before the open–––Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open–––Release
Q4 FY2024ended Dec 31, 2024Mar 19, 2025before the open–––Release
Q2 FY2024ended Jun 30, 2024Jul 31, 2024before the open–––Release
Q4 FY2023ended Dec 31, 2023Feb 28, 2024before the open–––Release
Q2 FY2023ended Jun 30, 2023Jul 31, 2023before the open–––Release
Q4 FY2022ended Dec 31, 2022Feb 28, 2023before the open–––Release
Q2 FY2022ended Jun 30, 2022Aug 1, 2022before the open–––Release
Q4 FY2021ended Dec 31, 2021Mar 3, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

HUTCHMED (China)'s latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Oncology/Immunology consolidated revenueFY2026$330.00M – $450.00M$330.00M – $450.00MReaffirmedJul 30, 2026

Guidance history

Every forecast HUTCHMED (China) put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Jul 30, 2026Oncology/Immunology consolidated revenueFY2026$330.00M – $450.00MReaffirmed
Mar 5, 2026Oncology/Immunology consolidated revenueFY2026$330.00M – $450.00MNew
Aug 7, 2025Oncology/Immunology consolidated revenueFY2025$270.00M – $350.00MLowered
Mar 19, 2025Oncology/Immunology consolidated revenueFY2025$350.00M – $450.00MNew
Jul 31, 2024growth target in oncology marketed product revenueFY2024+30% – +50%New
Jul 31, 2024Oncology/Immunology consolidated revenueFY2024$300.00M – $400.00MReaffirmed
Feb 28, 2024Oncology/Immunology consolidated revenueFY2024$300.00M – $400.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases HUTCHMED (China) filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K

See a number that looks wrong?